Mass drug administration can be a valuable addition to the malaria elimination toolbox

Malaria Journal

Volumn 18, Issue 1, 2019, Pages

  Eisele, Thomas P ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

Elimination; Malaria; Mass drug administration (MDA)

Indexed keywords

DISEASE ELIMINATION; DISEASE TRANSMISSION; EVIDENCE BASED PRACTICE; INCIDENCE; INFECTION PREVENTION; MALARIA; MALARIA CONTROL; MASS DRUG ADMINISTRATION; REVIEW; DISEASE ERADICATION; DRUG COMBINATION; DRUG RESISTANCE; ETHICS; HUMAN; PROCEDURES;

ANTIMALARIAL AGENT;

ANTIMALARIALS; DISEASE ERADICATION; DRUG COMBINATIONS; DRUG RESISTANCE; HUMANS; MALARIA; MASS DRUG ADMINISTRATION;

EID: 85071310949     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-019-2906-8     Document Type: Review

References (44)

1. WHO. World Malaria Report 2018. Geneva: World Health Organization; 2018.
2. WHO. Global Technical Strategy for Malaria 2016-2030. Geneva: World Health Organization; 2015.
3. Nguyen TN, von Seidlein L, Nguyen TV, Truong PN, Hung SD, Pham HT, et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis. 2018;18:565-72.
4. Okell LC, Ghani AC, Lyons E, Drakeley CJ. Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis. 2009;200:1509-17.
5. Okell LC, Bousema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237.
6. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife. 2018;7:e35832.
7. Gosling RD, Okell L, Mosha J, Chandramohan D. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011;17:1617-23.
8. WHO. Meeting report of the WHO Evidence Review Group on mass drug administration for malaria: 11-13, Geneva, Switzerland. Geneva: World Health Organization; 2018. p. 2019.
9. WHO. Guidelines: alternative mass drug administration regimens to eliminate lymphatic filariasis. Geneva: World Health Organization; 2017.
10. WHO. Accelarating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva: World Health Organization; 2012.
11. WHO. Preventive chemotherapy in human helminthiasis: coordinated use of anthelmintic drugs in control interventions: a manual for health professionals and programme managers. Geneva: World Health Organization; 2006.
12. Escudie A, Hamon J, Schneider J. Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone] (in French). Med Trop (Mars). 1960;1962(8):433-9.
13. Jones SA. Mass treatment with pyrimethamine; a study of resistance and cross resistance resulting from a field trial in the hyperendemic malarious area of Makueni, Kenya. September 1952-September 1953. Trans R Soc Trop Med Hyg. 1958;52:547-61.
14. Molineaux L, Gramiccia G. The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. Geneva: World Health Organization; 1980.
15. Singh J, Misra BG, Ray AP. Suppressive treatment with amodiaquin. Indian J Malariol. 1953;7:27-31.
16. Roberts JM. Pyrimethamine (Daraprim) in the control of epidemic malaria. J Trop Med Hyg. 1956;59:201-8.
17. Schneider J, Escudie A, Hamon J. The eradication of malaria and chemotherapy. Results of a trial of the combination: "4-aminoquinoline"/"8-aminoquinoline" in the "pilot zone" of Bobo-Dioulasso (Haute-Volta) (in French). Bull Soc Pathol Exot. 1961;54:1012-25.
18. von Seidlein L, Greenwood BM. Mass administrations of antimalarial drugs. Trends Parasitol. 2003;19:452-60.
19. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;12:CD008846.
20. Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. Am J Trop Med Hyg. 2015;93:125-34.
21. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A. Malaria eradication on islands. Lancet. 2000;356:1560-4.
22. Deng C, Huang B, Wang Q, Wu W, Zheng S, Zhang H, et al. Large-scale artemisinin-piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clin Infect Dis. 2018;67:1670-6.
23. Eisele TP, Bennett A, Silumbe K, Finn TP, Chalwe V, Kamuliwo M, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial. J Infect Dis. 2016;214:1831-9.
24. von Seidlein L, Peto TJ, Landier J, Nguyen TN, Tripura R, Phommasone K, et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. PLoS Med. 2019;16:e1002745.
25. Landier J, Kajeechiwa L, Thwin MM, Parker DM, Chaumeau V, Wiladphaingern J, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Res. 2017;2:81.
26. Zambia Ministry of Health. National Malaria Elimination Strategic Plan 2017-2021: a strategy to move from accelerated burden reduction to malaria elimination in Zambia (Brief). Lusaka: Zambia Ministry of Health; 2017.
27. Parker DM, Tun STT, White LJ, Kajeechiwa L, Thwin MM, Landier J, et al. Potential herd protection against Plasmodium falciparum infections conferred by mass antimalarial drug administrations. Elife. 2019;8:e41023.
28. Bretscher MT, Griffin JT, Ghani AC, Okell LC. Modelling the benefits of long-acting or transmission-blocking drugs for reducing Plasmodium falciparum transmission by case management or by mass treatment. Malar J. 2017;16:341.
29. Brady OJ, Slater HC, Pemberton-Ross P, Wenger E, Maude RJ, Ghani AC, et al. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob Health. 2017;5:e680-7.
30. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today. 1988;4:112-5.
31. WHO. Expert Committee on malaria: fifteenth report. Geneva: World Health Organization; 1970.
32. Zuber JA, Takala-Harrison S. Multidrug-resistant malaria and the impact of mass drug administration. Infect Drug Resist. 2018;11:299-306.
33. Kaehler N, Adhikari B, Cheah PY, Day NPJ, Paris DH, Tanner M, et al. The promise, problems and pitfalls of mass drug administration for malaria elimination: a qualitative study with scientists and policymakers. Int Health. 2019;11:166-76.
34. Chan XHS, Win YN, Mawer LJ, Tan JY, Brugada J, White NJ. Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018;18:913-23.
35. Morris U, Msellem MI, Mkali H, Islam A, Aydin-Schmidt B, Jovel I, et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission. BMC Med. 2018;16:215.
36. von Seidlein L, Dondorp A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev Anti Infect Ther. 2015;13:715-30.
37. White NJ. Does antimalarial mass drug administration increase or decrease the risk of resistance? Lancet Infect Dis. 2017;17:e15-20.
38. Carter R, Mendis KN, Roberts D. Spatial targeting of interventions against malaria. Bull World Health Organ. 2000;78:1401-11.
39. Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, et al. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012;9:e1001165.
40. Cohen JM, Le Menach A, Pothin E, Eisele TP, Gething PW, Eckhoff PA, et al. Mapping multiple components of malaria risk for improved targeting of elimination interventions. Malar J. 2017;16:459.
41. WHO. A framework for malaria elimination. Geneva: World Health Organization; 2017.
42. WHO. The role of mass drug administration, mass screening and treatment, and focal screening and treament for malaria. Geneva: WHO Global Malaria Programme; 2015.
43. Adhikari B, James N, Newby G, von Seidlein L, White NJ, Day NP, et al. Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. Malar J. 2016;15:523.
44. Hetzel MW, Genton B. Mass drug administration for malaria elimination: do we understand the settings well enough? BMC Med. 2018;16:239.